Stoke Therapeutics - STOK Net Assets per Single Share

Graphic logo of Stoke Therapeutics (STOK)

Stoke Therapeutics (STOK) operations are constrained by foreign policy risks and challenges with international patenting, as evidenced by the market dynamics of the securities at the 5.57 level. The brand is renowned for the impeccable trust physicians place in its RNA therapy developments. The business specializes in creating exclusive epilepsy drugs, ensuring stable demand through the production of life-saving medications.

Stoke (STOK) Equity per Share: for the period 07/04/2022 - 10/27/2026

stoketherapeutics.com - analytical breakdowns and key metrics (STOK)

- price and consensus price forecast:
Price Chart Stoke|STOK - Average Forecast Price
- market capitalization data:
Market Value Stoke Therapeutics, Inc.|STOK - Enterprise Value
- book capitalization data:
Book Value per Share Stoke Therapeutics|STOK - Accounting Capitalization|Market Value to Book Value Ratio stoketherapeutics.com|STOK - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Stoke Therapeutics|STOK - Long-Term Debt to Capital|Short-Term Debt to Equity Stoke Therapeutics, Inc.|STOK - Company Total Debt Obligations|Debt to Book Value Stoke Therapeutics, Inc.
Initial company analysis:STOK (Stoke)
Manufactured products of Stoke Therapeutics, Inc.

Stoke Therapeutics develops innovative drugs for the therapy of rare genetic pathologies at the RNA level. By analyzing the current book value per share, an investor can see the actual asset backing of each security. This metric is calculated as the ratio of net assets to the number of shares outstanding. This allows for an assessment of the business's intrinsic value beyond market fluctuations. This metric confirms the financial stability of Stoke Therapeutics within the capital-intensive segment of precision medicine.

Competitor analysis for Stoke Therapeutics

TEM (Tempus AI, Inc.) - Net Assets per Single Share|QGEN: Net Asset Value per Share|IONS: Net Assets per Single Share|repligen.com (RGEN) - Book Value per Share|Book Value per Share Avidity Biosciences, Inc. (RNA)|Equity per Share CRSP|Net Assets per Single Share Sema4 WGS|Equity per Share Ultragenyx Corp (RARE)|Book Value per Share BEAM (Beam Therapeutics Inc.)|sarepta.com - Book Value per Share|Net Assets per Single Share TWST (Twist Bioscience, Inc.)|10x Genomics Inc (TXG) - Net Assets per Share|NTLA - Accounting Value per Share|BLFS (BioLife) - Book Price of a Share|Net Assets per Single Share WVE (Wave Life Sciences)|Net Asset Value per Share MAZE|Net Assets per Single Share SION|Book Value per Share Prime Medicine Inc (PRME)|TSHA: Book Value per Share|QURE - Net Asset Value per Share|Accounting Value per Share MeiraGTx Holdings plc (MGTX)|regenxbio.com (RGNX) - Accounting Value of a Share|SLDB - Accounting Value per Share|Ocugen Inc (OCGN) - Book Price of a Share|PACB - Book Value per Share|Accounting Value of a Share Benitec Corp|Design Therapeutics - Book Value per Share|Net Asset Value per Share RCKT (rocketpharma.com)|Net Assets per Single Share 4D Molecular Therapeutics, Inc.|Accounting Value of a Share Lexeo Therapeutics Inc. LXEO|Korro Bio, Inc - Book Value per Share|EDIT: Book Value per Share|Net Assets per Single Share Silence Therapeutics (SLN)|ProQR Therapeutics (PRQR) - Share Book Value|Book Value per Share CDXS (Codexis Inc)|Net Asset Value per Share Sangamo Therapeutics Inc. (SGMO)|Accounting Value per Share NAUT|Book Value per Share Metagenomi Therapeutics MGX|Accounting Value per Share Precision BioSciences, Inc. (DTIL)|Book Price of a Share Generation Bio Co GBIO|Book Value per Share BOLD (Boundless Bio)|XCUR - Net Assets per Share|IMNN (imunon.com) - Book Value per Share|PHIO (Phio Pharmaceuticals Corp.) - Accounting Value per Share|MBIO: Net Assets per Single Share|Net Assets per Share RNAZ|BNGO (Bionano Genomics, Inc.) - Net Assets per Single Share|Net Assets per Share Applied DNA Sciences Inc APDN|Accounting Value per Share Bluebird Bio (BLUE)|ImmunoPrecise Antibodies Ltd - Book Price of a Share|OMGA (Omega Therapeutics) - Net Assets per Single Share|OMIC: Net Asset Value per Share|RGLS: Net Assets per Single Share|Syros Pharmaceuticals Inc. (SYRS) - Book Value per Share|Book Value per Share Codex DNA (TBIO)|Equity per Share TCON|Net Assets per Single Share Unity Biotechnology UBX